PGDT in Patients Undergoing Kidney Transplant

NACompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2023

Conditions
Kidney TransplantComplications
Interventions
PROCEDURE

PGDT

The minimally invasive continuous CI monitor (Edwards ClearSight) was used to guide an optimization of preload with the use of algorithms based on fluids, inotropes and/or vasopressors to achieve a certain goal in medium arterial pressure (MAP), cardiac index (CI) and stroke volume variation (SVV)

Trial Locations (2)

10126

Dipartimento di Anestesia e Rianimazione - Città della salute e della scienza, Torino, Torino

60126

SOD Anestesia e Rianimazione dei Trapianti e Chirurgia Maggiore, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I - GM Lancisi - G Salesi, Ancona

All Listed Sponsors
lead

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER

NCT05035537 - PGDT in Patients Undergoing Kidney Transplant | Biotech Hunter | Biotech Hunter